Vaxcyte, Inc.

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-12 pm EST			5-day change	1st Jan Change
54.95 ^USD	-0.72%		+1.93%	+19.09%

Feb. 11	Vaxcyte, Inc. Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines	CI
Feb. 02	Vaxcyte Closes Public Offering of Shares	MT

Vaxcyte Insider Sold Shares Worth $427,923, According to a Recent SEC Filing

Published on 01/07/2025 at 04:37 pm EST - Modified on 01/07/2025 at 04:38 pm EST

MT Newswires

Latest news about Vaxcyte, Inc.

Feb. 11	Vaxcyte, Inc. Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines	CI
Feb. 02	Vaxcyte Closes Public Offering of Shares	MT
Jan. 30	Vaxcyte Prices $550 Million Common Stock Offering	MT
Jan. 29	Vaxcyte Launches $500 Million Public Offering	MT
Jan. 22	Vaxcyte advances adult and infant programs for Vax-31, a potential best-in-class, next-generation pneumococcal conjugate vaccine	RE
Jan. 22	Vaxcyte, Inc. Advances Adult and Infant Programs for VAX-31, a Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine	CI
Dec. 08	Vaxcyte Doses First Patients in Phase 3 Trial of VAX-31 in Invasive Pneumococcal Disease, Pneumonia	MT
Dec. 08	Vaxcyte says topline results from OPUS trial expected in Q4 2026	RE
Dec. 08	Vaxcyte, Inc. Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults	CI
Dec. 01	Vaxcyte, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 02:30 PM
Dec. 01	Vaxcyte, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 02:30 PM
Dec. 01	Top Premarket Decliners	MT
Nov. 19	The AI Trade's Moment of Truth
Nov. 19	Analysts recommendations: Doordash, The Home Depot, Micron Technology, Quanta Services…
Nov. 04	Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-16	TSMC Keeps the Dream Alive
25-10-16	Analyst recommendations: Las Vegas Sands, Alphabet, Applovin, Carmax, United AIrlines…
25-09-30	Vaxcyte, Inc. to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services	CI
25-09-30	Vaxcyte to Expand Fill-Finish Manufacturing Capacity in US; Shares Up Pre-Bell	MT
25-09-30	Vaxcyte to Partner with Thermo Fisher to Increase Vaccine Production in U.S.	DJ
25-09-05	Vaxcyte, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 02:45 PM
25-09-03	Vaxcyte Says VAX-31 Pneumococcal Disease Study Advances to Final Stage	MT
25-09-03	Vaxcyte, Inc. Advances VAX-31 Infant Phase 2 Dose- finding Study with First Participants Receiving VAX-31 Optimized Dose	CI
25-08-06	Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-06	Vaxcyte, Inc. Appoints Chris Griffith as Chief Business and Strategy Officer	CI

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâ€™s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

414

Sector

Biotechnology & Medical Research

Calendar

Feb. 23 - Q4 2025 Earnings Release

More about the company